Norland bucks densitometry trend
Bone densitometry manufacturer Norland Medical Systems turned in financial results for the first quarter (end-March) that showed none of the problems that have been dogging other bone-mass measurement companies in recent weeks. For the period,
Bone densitometry manufacturer Norland Medical Systems turned in financial results for the first quarter (end-March) that showed none of the problems that have been dogging other bone-mass measurement companies in recent weeks. For the period, Norland had sales of $4.8 million, up 134% compared with $2.1 million in the first quarter of 1998. The firms net loss shrank to $615,000, compared with a net loss of $1.9 million in the same period the year before. Norland executives said the companys numbers should improve even further as it begins recognizing revenue from its new Excell dual-energy x-ray absorptiometry axial scanner, which began shipping in March.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
